Akèy › Kansè tete negatif triple › Indiana
Etid klinik pou Kansè tete negatif triple nan Indiana
13 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Indiana.
Vil nan Indiana
Tèks ofisyèl etid la (Anglè)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Northwest Cancer Center - Dyer Clinic ( Site 0097), Dyer
- Parkview Research Center at Parkview Regional Medical Center ( Site 0011), Fort Wayne
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne
- Franciscan Health ( Site 0077), Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Franciscan Health Indianapolis, Indianapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT05846789Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Goshen Center for Cancer Care, Goshen
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07211178A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06150664A Study of LY4175408 in Participants With Advanced Cancer
- Community Health Network, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
- Community Health Network, Inc. /ID# 243011, Indianapolis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05005403A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- Indiana University Simon Cancer Center, Indianapolis
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Apr 20, 2026 · NCT06134375NearWave Optical Molecular Monitoring
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Feb 17, 2026 · NCT06744465A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Community Health Network, Indianapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Northwest Cancer Center, Dyer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 19, 2025 · NCT06568692Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.